Global Cancer Immunotherapies Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
- SKU ID : GIR-GIR1807110156 12974459
- |
- Publishing Date: 16-Oct-2018
- |
- Region: Global
- |
- No. of pages: 129
Cancer immunotherapy is a type of cancer treatment that boosts the human bodys natural immune system to fight against the cancer cells. This therapy is provided to cancer patients to stop the spread of cancer, to slow down the growth of cancer cells, and to improve the natural immunity for destroying the cancer cells.
Scope of the Report:
This report studies the Cancer Immunotherapies market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cancer Immunotherapies market by product type and applications/end industries.
Rising R&D in cancer immunotherapy is resulting in introduction of advanced treatment options that are more effective and efficient. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall market.
The world cancer immunotherapy market is foretold to gain impetus due to rising popularity of patient assistance programs and broad portfolio of promising pipeline drugs. However, there could be more significant factors augmenting the demand in the market. For instance, rise in requirement of cancer monoclonal antibodies and launch of more effective bioinformatics tools offering improved drug development options could help with more demand for cancer immunotherapy. Furthermore, surge in adoption of immunotherapy therapeutics compared to conventional ones and high incidence of cancer could help the market to increase growth in the coming years.
The Americas accounted for approximately 47% of the market share of the global cancer immunotherapies market in 2015. High incidences of cancer in regions like the US, Canada, and Latin America are expected to contribute to the market growth in this region. region. This has led to an increase in consumption of immunotherapies that is used to treat cancer patients, thereby aiding the market growth.
The global Cancer Immunotherapies market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cancer Immunotherapies.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Amgen
Bristol Mayer’s Squibb
F. Hoffmann-La Roche
Merck
Takeda
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Monoclonal Antibodies
Cancer Vaccines
Check Point Inhibitors
Immunomodulators
Market Segment by Applications, can be divided into
Lung
Breast
Colorectal
Melanoma
Prostate
Head & Neck
Scope of the Report:
This report studies the Cancer Immunotherapies market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cancer Immunotherapies market by product type and applications/end industries.
Rising R&D in cancer immunotherapy is resulting in introduction of advanced treatment options that are more effective and efficient. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall market.
The world cancer immunotherapy market is foretold to gain impetus due to rising popularity of patient assistance programs and broad portfolio of promising pipeline drugs. However, there could be more significant factors augmenting the demand in the market. For instance, rise in requirement of cancer monoclonal antibodies and launch of more effective bioinformatics tools offering improved drug development options could help with more demand for cancer immunotherapy. Furthermore, surge in adoption of immunotherapy therapeutics compared to conventional ones and high incidence of cancer could help the market to increase growth in the coming years.
The Americas accounted for approximately 47% of the market share of the global cancer immunotherapies market in 2015. High incidences of cancer in regions like the US, Canada, and Latin America are expected to contribute to the market growth in this region. region. This has led to an increase in consumption of immunotherapies that is used to treat cancer patients, thereby aiding the market growth.
The global Cancer Immunotherapies market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cancer Immunotherapies.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Amgen
Bristol Mayer’s Squibb
F. Hoffmann-La Roche
Merck
Takeda
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Monoclonal Antibodies
Cancer Vaccines
Check Point Inhibitors
Immunomodulators
Market Segment by Applications, can be divided into
Lung
Breast
Colorectal
Melanoma
Prostate
Head & Neck
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
